FDA officials say real-world evidence could be used to expand cancer indications to tissue-agnostic, as well as demote them to tissue-specific. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
